Ocriplasmin is recombinant microplasmin protease being developed for pharmacological posterior vitreous detachment by cleaving the extracellular matrix that adheres the vitreous to the internal limiting membrane of the retina. In any condition where the vitreous can be abnormally adherent to the macula, leading to blindness from vitreomacular traction or macular hole it might have a role and thus be an option in exudative age-related macular degeneration, vitreomacular adhesion including macular holes, and macular oedema secondary to uveitis. It may facilitate penetration of anti-VEGF drugs into the retina.
Cautions and Interactions
- Retinal detachment seems rare.